Key result
Genotype-guided P2Y12 inhibitor selection after PCI lacks reported outcomes for East Asian versus Caucasian patients.
Why the study?
Tailored DAPT guided by genetic testing allows individualized treatment strategies after PCI, enabling evaluation of genotype-guided therapy.
RCT
Individualized DAPT escalation or de-escalation may optimize net benefit in selected PCI patients; leaves open optimal guided strategies pending dedicated trials.
In patients undergoing percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) with aspirin and P2Y 12 receptor inhibitor is the standard treatment to prevent occurrence of atherothrombotic event.Clinical application of different P2Y 12 receptor inhibitors (clopidogrel, prasugrel or ticagrelor) with varying levels of antiplatelet potency has enabled physicians to consider individualized treatment strategies, which may include escalation or de-escalation of P2Y 12 receptor inhibitor (1).A tailored DAPT approach may be possibly guided by platelet function testing (PFT) or genetic testing (2).The data of the TAILOR-PCI (Tailored Antiplatelet Therapy Following PCI) trial evaluated clinical efficacy and safety of genotype-guided strategy (potent P2Y 12 receptor inhibitor in cases with CYP2C19 loss-of-function allele) vs.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2020) conducted an RCT in percutaneous coronary intervention (PCI). genotype-guided strategy was evaluated. A genotype-guided strategy for P2Y12 receptor inhibitor selection was evaluated in East Asian versus Caucasian patients after PCI, but quantitative results are not reported in the truncated abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: